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Summary
Background Amid rapid urbanisation, the HIV epidemic, and increasing rates of non-communicable diseases, people 
in sub-Saharan Africa are especially vulnerable to kidney disease. Little is known about the epidemiology of chronic 
kidney disease (CKD) in sub-Saharan Africa, so we did a systematic review and meta-analysis examining the 
epidemiology of the disease. 
Methods We searched Medline, Embase, and WHO Global Health Library databases for all articles published through 
March 29, 2012, and searched the reference lists of retrieved articles. We independently reviewed each study for 
quality. We used the inverse-variance random-eﬀ ects method for meta-analyses of the medium-quality and high-
quality data and explored heterogeneity by comparing CKD burdens across countries, settings (urban or rural), 
comorbid disorders (hypertension, diabetes, HIV), CKD deﬁ nitions, and time. 
Findings Overall, we included 90 studies from 96 sites in the review. Study quality was low, with only 18 (20%) 
medium-quality studies and three (3%) high-quality studies. We noted moderate heterogeneity between the medium-
quality and high-quality studies (n=21; I²=47·11%, p<0·0009). Measurement of urine protein was the most common 
method of determining the presence of kidney disease (62 [69%] studies), but the Cockcroft-Gault formula (22 [24%] 
studies) and Modiﬁ cation of Diet in Renal Disease formula (17 [19%] studies) were also used. Most of the studies 
were done in urban settings (83 [93%] studies) and after the year 2000 (57 [63%] studies), and we detected no 
signiﬁ cant diﬀ erence in the prevalence of CKD between urban (12·4%, 95% CI 11–14) and rural (16·5%, 13·8–19·6) 
settings (p=0·474). The overall prevalence of CKD from the 21 medium-quality and high-quality studies was 13·9% 
(95% CI 12·2–15·7).
Interpretation In sub-Saharan Africa, CKD is a substantial health burden with risk factors that include communicable 
and non-communicable diseases. However, poor data quality limits inferences and draws attention to the need for 
more information and validated measures of kidney function especially in the context of the growing burden of non-
communicable diseases. 
Funding Duke University.
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Introduction
Amid population ageing, lifestyle changes, and rapid 
urbanisation, the importance of non-communicable 
diseases in low-income and middle-income countries is 
becoming increasingly recognised, and in 2011 the 
United Nations General Assembly adopted a resolution 
acknowledging the impending global burden and threat 
of non-communicable diseases.1 However, few epi-
demiological studies of the incidence, prevalence, and 
cause of these diseases have been done.1–3 Chronic kidney 
disease (CKD), which nearly doubled as a cause of death 
worldwide between 1990 and 2010 and was the 18th 
highest cause of death worldwide in 2010, falls into this 
category of diseases.4 
Sub-Saharan Africa is a vast and heterogeneous 
region of roughly 24 million km² composed of 
47 countries and more than 900 million people.5 By 
2030, more than 70% of patients with end-stage renal 
disease are estimated to be living in low-income 
countries, such as those in sub-Saharan Africa, where 
the gross domestic product per person is on average 
less than US$1500 per year.6–8 This estimation is 
alarming in view of the fact that the global prevalence 
of maintenance dialysis has doubled since 1990, and 
that renal replacement therapy was accessed by 
1·8 million people worldwide in 2004 with less than 5% 
of that population coming from sub-Saharan Africa.9,10
There are many potential causes of CKD in sub-
Saharan Africa, making kidney disease especially 
burdensome in the region. In addition to non-
communicable diseases, communicable diseases 
such as infectious glomerulonephritis, schistosomiasis, 
leishmaniasis, and HIV infection are common and can 
cause CKD. And because more than 22 million people in 
sub-Saharan Africa have HIV, the potential for an 
overwhelming burden of CKD in the region is high.11–14  
As has been noted elsewhere,15,16 the challenging ﬁ rst 
step to address the burden of kidney disease in Africa is to 
establish the epidemiology of CKD. We hypothesised that 
CKD is an important disease in sub-Saharan Africa with 
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many potential causes. To assess the extent to which it is a 
public health and economic burden, we did a systematic 
review and meta-analysis to ﬁ nd out the prevalence of 
CKD in adults in the region.
Methods
Search strategy and selection criteria  
We followed the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines.17 We searched PubMed, Embase, and the 
WHO Global Health Library databases (which include 
the African [AFRO] Index Medicus, WHO Library 
Information System [WHOLIS], and Scientiﬁ c 
Electronic Library Online [SciELO]) for published 
reports of kidney disease in sub-Saharan Africa up to 
March 29, 2012. We used Boolean logic with search 
terms including “chronic kidney disease”, 
“nephropathy”, “renal insuﬃ  ciency”, and “Africa south 
of Sahara”. We used controlled vocabularies (eg, Medical 
Subject Heading terms) to identify synonyms. We 
applied no language restrictions. The study protocol and 
detailed search parameters are available in the appendix.
Two authors (JWS and RM) independently reviewed 
each title and abstract for inclusion. Randomised 
controlled trials and non-randomised studies including 
cross-sectional studies, cohort studies (retrospective and 
prospective), case-control studies, and literature reviews 
that report a prevalence or a calculable prevalence for 
CKD in adults from a sub-Saharan African country were 
eligible for inclusion. We excluded studies that were only 
composed of pregnant women or people admitted to 
hospital, or ones that speciﬁ cally recruited participants 
on the basis of the presence or absence of kidney disease. 
We regarded the following terms as equivalent to chronic 
kidney disease: “renal insuﬃ  ciency”, “chronic kidney 
failure”, “renal impairment”, “end/target-organ damage” 
(if renal function was recorded in some capacity), 
“end-stage kidney/renal disease”, “nephropathy”, 
“proteinuria”, “dialysis-dependent”, “status-post renal 
transplant”, “sonographic-evidence”, and “biopsy-proven 
renal disease”. 
Two investigators (JWS and ST) did a second review 
assessing entire papers and their reference lists. Any 
disagreement resulted in joint review of the article with 
reconciliation. Articles in French were translated by one 
author (NH) and then independently reviewed by two 
authors (JWS and ST or JWS and RM) for inclusion and 
extraction (only one article was not in French or English, 
and it was excluded on the basis of title and abstract 
alone). Detailed inclusion and exclusion criteria are 
available in the appendix. 
Quality assessment and data extraction  
Three authors (JWS, ST, and RM) independently 
appraised each article for quality using previously 
described assessment criteria (panel).18–23 On the basis of 
these criteria, each article received a quality grade of low, 
medium, or high, and any disagreement resulted in joint 
review of the article.
Data were extracted from all included studies by two 
authors independently (JWS and ST) and in duplicate 
into a preformulated table; errors of data extraction were 
resolved by joint review of the original articles. In 
addition to the overall prevalence reported by each study, 
we extracted or calculated, as necessary, the prevalence of 
CKD as deﬁ ned by proteinuria, a creatinine clearance of 
less than 60 mL per min by the Cockcroft-Gault formula, 
See Online for appendix
Panel: Quality assessment criteria for studies examining the prevalence of chronic 
kidney disease
High quality
For studies of the highest quality, assessors should answer yes to the following ten questions
1 Subject sampling and precision
A Are the included people representative of the general population? (Comment: 
if people were included on the basis of hospital records, insurance claims, or 
health-care facilities then they should not be considered representative of the 
general population.)
B People are not included or excluded on the basis of speciﬁ c risk factors. (Comment: 
high risk people such as those with diabetes, HIV, or hypertension should not be 
sought out speciﬁ cally for inclusion or exclusion.)
C Is the sam ple size adequate to address the question of prevalence in the studied 
population?
2 Sampling technique
A Were the people recruited at random? (Comment: methods should address the 
issue of enrolling consecutive participants, people likely to have the disease or at 
high risk, and convenience sampling)
3 Response rate
A Does the article report a response rate in total sample?
B Is that response rate 40% or higher?
4 Exclusion rate
A Does the article report an exclusion rate in total sample?
B Is the exclusion rate 10% or less?
5 Measurement and method of determination of kidney disease
A Does the study report the method used for determination of kidney disease?
B Does the study use a consistent method for determination of kidney disease?
Medium quality
For studies of medium quality, assessors should answer yes to the following questions
1 If participants are not representative of the general population, then are they 
representative of the population in question? (Comment: people can be taken from 
high-risk groups such as diabetic or hypertensive populations; although not considered 
representative of the entire population, they can still be representative of that speciﬁ c 
population.)
2 If participants were not recruited at random, then were they recruited in a random 
non-health-care convenience method from the entire population in question?
3 Is the study sample size adequate to answer the question of prevalence in the studied 
population?
4 Does the study use a consistent method for determination of kidney disease?
Low quality
1 For studies of the lowest quality, assessors would be unable to answer yes to all of the above 
questions.
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or an estimated glomerular ﬁ ltration rate (GFR) of less 
than 60 mL per min per 1·73 m² by the Modiﬁ cation of 
Diet in Renal Disease (MDRD) and Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) 
formulae. Although prevalence was the primary 
summary measure of interest, we also extracted the 
following information from each study: authors, location, 
setting, study population, dates, comorbidities, sample 
size, methods of measurement for kidney disease, mean 
age, and sex. If studies did not specify the exact years of 
study, we used the year of publication. We extracted or 
calculated these speciﬁ c data only when we were able to 
conﬁ dently establish that patients were not overlapping 
or being counted twice. In cases of uncertainty or missing 
data, we contacted the corresponding authors for 
additional information.
Statistical analysis
We investigated heterogeneity using an I² statistic and 
completed meta-analyses with the inverse-variance 
random-eﬀ ects method, as described by DerSimonian and 
Laird.24 Each study prevalence estimate received a weight 
that was equal to the reciprocal of within-study variance (vi) 
summed with between-study variance (τ²). The calculated 
tau-squared (τ²) or between-study variance for our analysis 
was 0·010766. Only medium-quality and high-quality 
studies were included in the meta-analyses. We then 
calculated pooled prevalence as a weighted mean among 
all the study estimates. We examined prevalence by region, 
country, method of kidney disease measurement, setting 
(urban or rural), date, and disease-speciﬁ c populations 
(HIV, hypertension, and diabetes type 1 and 2).
We assessed inter-rater agreement for inclusion using 
Cohen’s kappa (κ) coeﬃ  cient, and assessed inter-rater 
agreement for quality assessment using Fleiss’s κ 
statistic. We calculated 95% CIs using Wilson’s score 
method. This method for determination of two-sided CIs 
of proportions (prevalence) prohibits overshoot of zero or 
one and is applicable to all sample sizes.25,26 We used a 
Welch two-sided t test and Wilcoxon rank sum test to 
compare prevalence estimates between groups. All 
continuous variables were reported as mean (SD). We 
used R (version 2.15.0; rmeta package) for all statistical 
analyses. 
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all the 
data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
We identiﬁ ed 905 articles, of which 90 were included in 
the systematic review (ﬁ gure 1; appendix). Inter-rater 
agreement for inclusion was excellent (κ=0·974), and any 
disagreement resulted in inclusion for full text review.
The 90 articles, done between 1962 and 2011, reported 
data for 21 countries with a geographical distribution 
covering most of sub-Saharan Africa. However, more 
than half the studies (48 [53%] studies) were from South 
Africa, Nigeria, and Ethiopia. Data for 64 307 people (42% 
men) were included, with a mean age of 41·4 years 
(SD 9·9). 46 494 (72%) people had diabetes, 37 169 (58%) 
had HIV, 7845 (12%) had hypertension, and 2765 (4%) 
were obese (body-mass index  [BMI]>30 kg/m²). 
18 (20%) studies27–44 from 25 sites met criteria for the 
medium level of quality, and three (3%) studies45–47 met 
criteria for the high level of quality. Inter-rater agreement 
for quality assessment was excellent (κ=0·916). The 
common reasons for studies not meeting the criteria were 
the sampling methods used, most commonly convenience 
sampling, and unreliable measurements of kidney 
function. Most studies (72 [80%] studies) examined 
populations thought to be high risk—eg, people with HIV, 
diabetes, hypertension, or other risk factors for kidney 
disease. The studies assessed kidney function by urine 
protein (62 [69%] studies), estimation of creatinine 
clearance by Cockcroft-Gault formula (22 [24%] studies), 
and estimation of GFR by MDRD formula (17 [19%] 
studies). Less often, biopsy (two [2%] studies) and 
calculation of GFR by CKD-EPI formula (two [2%] studies) 
were also used. Other measurements of kidney function 
included simple chart review, absolute creatinine value, 
Figure 1: Flow diagram of study selection
* WHO Global Health Library databases include the African Index Medicus, Medline, World Health Organization 
Library Information System (WHOLIS), and Scientiﬁ c Electronic Library Online (SciELO).
905 articles retrieved for analysis
638 from Medline
138 from Embase 
129 from WHO Global
Health Library
365 full-text articles assessed 
for eligibility 
275 from Medline
57 from Embase 
33 from WHO Global
Health Library
851 articles screened based on 
title and abstract
90 articles from 96 sites included 
in the systematic review
3 articles from review 
of bibliographies
54 duplicate articles 
486 articles did not meet 
inclusion criteria 
69 low-quality articles
excluded from 
meta-analyses
21 medium-quality and 
high-quality articles from 
25 sites included in the 
meta-analyses
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and presence of azotaemia as indicated by absolute blood 
urea nitrogen value. A third of studies (30 [33%] studies) 
measured kidney function by more than one method.
The overall prevalence of CKD from the 21 medium-
quality and high-quality studies was 13·9% 
(95% CI 12·2–15·7; ﬁ gure 2). Estimates ranged from 2% 
in Cote d’Ivoire to 30% in Zimbabwe. Nearly half (n=6) 
the countries represented had prevalence estimates 
ranging between 4% and 16%, and all countries but one 
(Zimbabwe) had prevalence estimates of less than 20% 
(ﬁ gure 2). In the case of Zimbabwe, the estimate is 
derived from only one study that included many people 
with HIV who had not received antiretroviral treatment, 
which probably explains the unusually high prevalence.29 
The only other study to have measured a prevalence of 
CKD in Zimbabwe was a convenience sample of people 
with diabetes and was not included in the meta-analysis 
due to its low quality. We formally noted heterogeneity 
across the medium-quality and high-quality studies 
(n=21; I²=47·11%, p=0·0009; ﬁ gure 2). Heterogeneity 
across all studies was much higher (I²=67·64%, p=0·0051).
For many countries (Malawi, Burundi, Ethiopia, 
Tanzania, Benin, Burkina-Faso, Guinea, and Senegal) we 
detected no medium-quality or high-quality estimates for 
the prevalence of CKD. For instance, although nine 
studies were done in Ethiopia, including more than 
4000 people, all were convenience samples in people 
with diabetes or HIV (table). Additionally, even though 
we report estimates for Sudan, Nigeria, and South Africa, 
most studies from these countries were not included in 
the combined analysis due to issues with convenience 
sampling of high-risk populations and inconsistent 
measurements of kidney function.  
Of the three studies that met criteria for the highest 
quality grade, one was from Ghana and two were from 
the Democratic Republic of Congo (DRC). Both studies 
from DRC were done in an urban setting between 2006 
and 2007 and reported proteinuria prevalence to be 5% 
and 17%, respectively.45,46 Only one of the studies estimated 
GFR, and it showed that the prevalence of CKD when 
deﬁ ned as a GFR of less than 60 mL per min per 1·73 m² 
by the MDRD formula was 7·8% (95% CI 
7·6–8·1).45 The one high-quality study from Ghana was 
done in a rural population in 2010 and reports a CKD 
prevalence of 30% when deﬁ ned as a GFR of less than 
90 mL per min per 1·73 m² by the MDRD formula but 
only 1·6% when deﬁ ned as a GFR of less than 
60 mL per min per 1·73 m².47 
The method of measuring kidney disease also aﬀ ected 
the prevalence estimates across countries (table). 
Measurement of urine protein was the most common 
method of determining the presence of kidney disease 
(69%). Among medium-quality and high-quality studies, 
the prevalence of proteinuria ranged between 6% in 
Sudan to 24% in Zambia. The estimate from Cameroon 
is derived by pooling two arms (one urban and one rural) 
from one case-control study that was designed to 
compare the prevalence of nephropathy in an 
onchocerciasis-endemic area, and the estimate from 
Ghana is derived from only one medium-quality study 
done in an urban population that was speciﬁ cally 
designed to measure end-organ damage such as 
proteinuria in people with hypertention.41,43 The one 
high-quality study from Ghana did not measure 
proteinuria.47
Among the studies reporting both Cockcroft-Gault and 
MDRD formulae (n=10), estimates derived from the 
Cockcroft-Gault formula were higher in every study, 
although not signiﬁ cantly so (p=0·080), with the diﬀ erence 
less apparent for people with a creatinine clearance and 
GFR between 60 and 90 (p=0·170). Only two studies, one 
medium-quality study from Rwanda and one high-quality 
study from Ghana, reported estimated GFR by the CKD-
EPI formula, and they reported estimates that were similar 
to those reported by the MDRD formula (p>0·900 for 
diﬀ erence) at a GFR of less than 60 mL per min per 1·73 m² 
and GFR 60–90 mL per min per 1·73 m².27,47 We could not 
further characterise the extent to which people with an 
estimated GFR of less than 60 mL per min per 1·73 m² had 
concurrent proteinuria. 
The table shows the results for each country stratiﬁ ed 
by comorbidity. Among people with HIV, the prevalence 
of CKD was highest in Nigeria, Zimbabwe, and Uganda 
(table 1). The remaining countries of Cameroon, Côte 
d’Ivoire, Kenya, Mozambique, Rwanda, South Africa, 
and Zambia had prevalence estimates of 1–10%. The 
diﬀ erence between these two sets of countries might be 
related to the treatment status of the HIV participants. 
Only 16% of the participants in the studies from Nigeria, 
Zimbabwe, and Uganda were receiving care for their 
HIV, whereas all participants from the remaining 
countries were receiving some form of care for HIV.
In people with diabetes or hypertension in DRC, 
Ghana, Nigeria, Rwanda, South Africa, Sudan, and 
Figure 2: Forest plot of random-eﬀ ects meta-analyses showing the pooled 
prevalence of chronic kidney disease by country
Cameroon
DR Congo
Ghana
Côte d’Ivoire
Kenya
Mozambique
Nigeria
Rwanda
South Africa
Sudan
Uganda
Zambia
Zimbabwe
Overall (I2=47·11%)
Prevalence (95% CI)
0·061
0·198
0·170
0·020
0·040
0·030
0·176
0·100
0·143
0·080
0·181
0·130
0·302
0·139
(0·046–0·081)
(0·177–0·221)
(0·142–0·203)
(0·008–0·047)
(0·021–0·073)
(0·013–0·069)
(0·140–0·219)
(0·082–0·122)
(0·119–0·170)
(0·053–0·118)
(0·162–0·201)
(0·123–0·137)
(0·274–0·331)
(0·122–0·157)
0·1 0·15 0·20·05 0·25 0·3
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Zambia, the prevalence of CKD ranged from 4% to 24% 
(table), with proteinuria almost exclusively used (96%) as 
the marker.  
The vast majority of studies were done in an urban 
setting (83 [93%] studies). Of the seven studies done in 
rural settings, most were of medium quality (n=6)27,31,32,37,38,43 
and one was high quality.47 Of the studies done in urban 
settings, only 13 (16%) met criteria for either 
medium28–30,33–36,39–42 or high quality.45,46 We detected no 
diﬀ erence in the prevalence of CKD between urban 
(12·4%, 95% CI 11–14) and rural (16·5%, 13·8–19·6) 
settings (p=0·474). 
Examination of the prevalence by decade suggested 
that CKD prevalence increased in each of the four 
previous decades. However, deﬁ nitive conclusions are 
limited by low study quality, detection bias, and 
publication bias that prevent meaningful analysis. Only 
eight studies were done before 1980 and only 31 studies 
were done between 1980 and 1999; 57 studies were done 
in the 2000s. Before the year 2000, only ﬁ ve medium-
quality studies and no high-quality studies were 
done.28,35,39,40,43  
Discussion
Our systematic analysis of available studies showed that 
CKD is a prevalent and potentially escalating disease 
across sub-Saharan Africa with risk factors that include 
both communicable and non-communicable diseases. 
Although use of diﬀ erent measurement and sampling 
methods limit direct comparison between studies, 
 Study quality 
(number of 
studies)*
Number 
of people
Mean age 
(years)
Population characteristics Prevalence by method of chronic 
kidney disease measurement
Prevalence by disease-speciﬁ c 
population
Male
(%)
Diabetes 
(%)
HIV
(%)
Hyper-
tension 
(%)
Proteinuria Modiﬁ cation 
of Diet in 
Renal Disease
Cockcroft-
Gault
Diabetes HIV Hyper-
tension
Eastern region
Burundi Low (1) 245 40 30% 2% 100% 3% ·· ·· ·· ·· ·· ··
Ethiopia Low (9) 4072 47·3 55% 96% 4% 12% ·· ·· ·· ·· ·· ··
Kenya Medium (1)38 235 30 31% ·· 100% ·· ·· ·· 4% ·· 4·0% ··
Malawi Low (2) 1048 43·4 35% 50% 57% 29% ·· ·· ·· ·· ·· ··
Mozambique Medium (1)38 163 30 31% ·· 100% ·· ·· ·· 3% ·· 3·0% ··
Rwanda Medium (1)27 865 ·· ·· 1% 76% 6% 7% 2% 25% ·· 10% ··
Tanzania Low (3) 968 45·4 48% 63% 37% 16% ·· ·· ·· ·· ·· ··
Uganda Medium (2);29,38 
low (1)
3277 34·5 34% ·· 100% 1% ·· 3·2% 6·7% ·· 18% ··
Zambia Medium (3);28,38,42 
low (1)
26 781 37·7 40% 2% 97% 1% 24% 3·1% 6·9% 24% 7·7%
Zimbabwe Medium (1);29 low (1) 1074 38 43% 7% 93% ·· ·· 3·2% 7·2% ·· 30·2% ··
South Africa Medium (4);37–40 
low (13)
5600 46 41% 40% 38% 30% 19% ·· 1% 18.9% 10% 24%
Western region
Benin Low (1) 152 53·5 66% 100% ·· ·· ·· ·· ·· ·· ·· ··
Burkina-Faso Low (2) 430 55 31% 92% 17% ·· ··
Ghana High (1);47 
medium (1);41 low (3)
2534 53·8 35% 18% ·· 54% 13·0% 2·1 21% 17% ·· 4%
Guinea Low (1) 116 49 66% 89% ·· 34% ·· ·· ·· ·· ·· ··
CÔte d’Ivoire Medium (1);38 low (2) 1683 42·5 50% 72% 14% 21% ·· ·· 2% ·· 2·0% ··
Nigeria Medium (5);32,33,35,36,44 
low (17)
5005 45·1 49% 34% 25% 25% 18% 10% 13·2% 7·3% 38% 23·1%
Senegal Low (1) 587 41 60% 54% ·· ·· ·· ·· ·· ·· ·· ··
Sudan Medium (1);30 low (5) 2011 37·2 44% 29% ·· 8% 6% 3% 6% 8% ·· ··
Central region
Cameroon Medium (3)38,43 2194 30 41% ·· ·· 13% 7·3% ·· 4% ·· 4·0% ··
DRC High (2);45,46 
medium (1);31 low (5)
5267 50·6 50% 25% 10% 33% 16·0% 8·6% 15·0% 19·8% ·· 19·9%
All countries, 
by study quality
Low (68); 
Medium (25); 
High (3)
15 939;
39 680;
4465
37;
35;
45·9
33%;
39%;
52%
60%;
6%;
6%
25%;
82%;
··
23%;
4%;
16%
·· ·· ·· ··;
14·1%;
19·8%
··;
11·9%;
··
··;
18·8%;
14·8%
DRC=Democratic Republic of Congo. *References for low-quality studies given in the appendix. 
Table: Chronic kidney disease in sub-Saharan Africa by country and comorbidity
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examination of the medium-quality or high-quality 
studies suggests that the estimated prevalence in many 
sub-Saharan African countries might approximate those 
in other low-to-middle-income countries in southeast 
Asia such as Taiwan, Vietnam, Malaysia, and India as 
well as the Latin American countries of Mexico, Brazil, 
and Uruguay.48–53 Additionally, it also implies that CKD 
might not be a burden exclusive to high-income regions.54 
Poor quality data for the prevalence of CKD in sub-
Saharan Africa was pervasive, and our review identiﬁ ed 
that the major reasons were related to poor sampling 
methods, unreliable kidney function measurements, and 
variable data availability in each country. Together, our 
ﬁ ndings draw attention to an important limitation to 
systematically addressing an increasing health problem 
throughout sub-Saharan Africa. 
Non-communicable diseases are thought to be a rising 
global epidemic that disproportionally aﬀ ect the economic, 
social, and health outcomes of resource-poor countries 
and low-income populations.55 For sub-Saharan Africa, 
conservative projections for the year 2030 predict that 
18·65 million people will have diabetes, and predictions 
for hypertension, obesity, and tobacco use are similarly 
alarming.56–59 In the context of CKD, these are portentous 
forecasts in view of the high burden of CKD in people 
with diabetes or hypertension shown in our analysis.  
Communicable diseases such as HIV might also be 
contributing to the large burden of CKD in sub-Saharan 
Africa. Management of chronic diseases in people living 
with and receiving treatment for HIV is becoming a 
challenge because fewer people die from HIV-related 
complications and more develop chronic diseases. This 
recognition has led to a strong international 
commitment to integrate HIV with the care of non-
communicable diseases.60 Our ﬁ ndings suggest that 
CKD is among the important potential chronic 
complications of HIV in sub-Saharan Africa. HIV 
treatment for the 22 million people with the infection in 
sub-Saharan Africa has become an urgent issue within 
the global community. However, our ﬁ ndings suggest 
that the prevalence of CKD is substantial even in people 
receiving care for HIV, which further substantiates the 
call to integrate HIV treatment with the care of non-
communicable diseases.14
An important diﬃ  culty in the detection and 
management of CKD in sub-Saharan Africa is the 
absence of reliable and validated measures of kidney 
function. Our ﬁ ndings show that, depending on the 
method of measurement or deﬁ nition of kidney 
impairment, prevalence estimates can vary substantially 
even within similar populations, and although the CKD-
EPI and modiﬁ ed CKD-EPI formulae have been 
suggested to most closely approximate GFR in many 
African populations, they have been applied in only two 
prevalence studies and remain unvalidated.27,47,61 
Proteinuria is another important and easily obtained 
clinical indicator of glomerular disease and might 
portend increased cardiovascular risk in people with 
HIV, diabetes, or hypertension. However, the best 
method of urinary protein detection remains unknown, 
and our ﬁ ndings showed that the variability and dearth of 
available data are major limitations. Nonetheless, our 
results still suggest that, when measured, the prevalence 
of proteinuria in people with diabetes, hypertension, or 
HIV is substantial, which again stresses a need for the 
integration of HIV and non-communicable diseases.  
The major strength of our study was the comprehensive 
inclusion of many studies with a transparent assessment 
of CKD prevalence in sub-Saharan Africa. Because of the 
shortage of high-quality data, we chose not to limit our 
systematic review to any particular population, time 
period, or measurement of kidney disease. We saw much 
heterogeneity between studies, which is a common 
ﬁ nding in many meta-analyses. Wherever possible, we 
presented the prevalence estimates descriptively in many 
diﬀ erent contexts to account for this heterogeneity, and 
we believe that exclusion of the low-quality studies from 
the review would have provided a restricted and false 
representation of the full state of renal epidemiology in 
sub-Saharan Africa. However, because such heterogeneity 
presented a less than ideal setting for pooling of data, we 
limited the meta-analyses to only studies of medium or 
high quality, and we felt that the absence of continent-
wide epidemiological data for kidney disease justiﬁ ed the 
method. The lack of reliable measures of kidney function 
was a major limitation of systematically reviewing the 
prevalence of kidney disease in sub-Saharan Africa, but 
this ﬁ nding has drawn attention to the large gap in 
reliable and validated estimates of kidney function. 
Additionally, we did not review articles in non-indexed 
journals, which might have introduced a slight 
publication bias.
There are many other implicated causes of CKD in sub-
Saharan Africa that we were not able to analyse, including 
chronic glomerulonephritis and the widespread use of 
herbal or traditional medication. Up to 80% of the 
populations in sub-Saharan countries are estimated to 
use herbal or traditional medicines, which are thought to 
have been associated with 35% of all new cases of acute 
kidney injury. Some of the most commonly used toxic 
herbs used as drugs are Securidaca longepedunculata 
(African violet tree), Cape aloes, and Euphorbia 
matabalensis, but few follow-up studies have been done 
on kidney disease caused by these agents.62–64 
On a continent where chronic diseases and 
cardiovascular deaths are now drawing increasing 
attention, CKD should not be overlooked. Approaches to 
addressing the rising epidemic of non-communicable 
diseases might initially include screening for CKD in 
speciﬁ c high-risk populations, especially in view of the 
fact that cardiovascular disease and chronic kidney 
disease share many common risk factors.58,65,66 Such 
might be especially important when considering that the 
incidence of end-stage renal disease, an almost uniformly 
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fatal disease in sub-Saharan Africa, mirrors the 
prevalence of non-communicable diseases in high-
income countries.7,16 Although poor data quality limit 
deﬁ nitive inferences, our ﬁ ndings suggest that CKD is a 
substantial health burden in sub-Saharan Africa with 
many risk factors, including many communicable and 
non-communicable diseases. These ﬁ ndings are of 
global interest and should signal a call to action. 
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